AngioDynamics Forecasts Fiscal Year 2025 Sales Of $282M-$288M, Representing Growth Of 4.2% – 6.4% Over Fiscal 2024 Pro Forma Revenue Of $270.7M Versus Consensus Of $287.68M
Portfolio Pulse from Benzinga Newsdesk
AngioDynamics forecasts fiscal year 2025 sales of $282M-$288M, representing growth of 4.2% – 6.4% over fiscal 2024 pro forma revenue of $270.7M. Med Tech net sales are expected to grow 10%-12%, Med Device net sales 1%-3%. Gross margin is projected to be 52%-53%, with an adjusted EBITDA loss of $2.5M to $0, compared to a pro forma adjusted EBITDA loss of $3.2M in fiscal 2024.
July 16, 2024 | 10:47 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AngioDynamics forecasts fiscal year 2025 sales of $282M-$288M, representing growth of 4.2% – 6.4% over fiscal 2024 pro forma revenue of $270.7M. Med Tech net sales are expected to grow 10%-12%, Med Device net sales 1%-3%. Gross margin is projected to be 52%-53%, with an adjusted EBITDA loss of $2.5M to $0, compared to a pro forma adjusted EBITDA loss of $3.2M in fiscal 2024.
The forecasted growth in sales and improvement in adjusted EBITDA loss indicate positive financial performance for AngioDynamics. The projected growth in Med Tech and Med Device sales, along with stable gross margins, suggest a strong outlook for the company. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100